98%
921
2 minutes
20
Silymarin (SLM) is a bioactive, water-insoluble flavonoid reported against different types of cancer. In the present research, the SLM inclusion complex was prepared by the freeze-drying method using different cyclodextrins. The phase solubility study was performed to assess the stability constant and complexation efficiency. The prepared SLM inclusion complexes (F1, F2, and F3) were characterized for different physicochemical and in vitro parameters. Based on the results, the selected inclusion complex (F2) was converted to a topical gel. Finally, it was evaluated for antioxidant, protein denaturation, and cell viability assay (B16F10; skin cancer cell line). The in vitro results were further confirmed by performing a molecular docking study. The phase solubilization results showed the formation of a stable complex with a stability constant value of 548 mol L (βCD-PLX), 911 mol L (HP βCD-PLX), and 736 mol L (M βCD-PLX). A marked increase in release pattern was found from the prepared inclusion complex (80.9 ± 2.2-97.8 ± 3.1%) compared to free SLM (24.1 ± 2.8%). DSC as well as the IR studies confirm the formation of a stable complex. SEM and X-ray diffraction results confirmed the conversion to the amorphous form. The molecular docking studies exhibited the high docking score of SLM with both colchicine-binding sites of the tubulin protein (-6.28 kcal/mol) and complexing agents, viz., βCD (-4.61 kcal/mol), HP βCD (-5.77 kcal/mol), and M βCD (-5.61 kcal/mol). The antioxidant assay results showed that the activity was significantly improved (1.2-1.6 fold) compared to free SLM. The in vitro cell viability assay outcome displayed concentration-dependent activity with a significantly lower IC50 value from F2G2 (145.3 ± 4.2 μg/mL) than free SLM (304.7 ± 5.7 μg/mL). The above conclusions demonstrated that the developed SLM inclusion complex-based gel system could be an ideal delivery system for skin cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780436 | PMC |
http://dx.doi.org/10.1021/acsomega.4c09614 | DOI Listing |
Am J Case Rep
September 2025
Department of Ophthalmology, Brasília University Hospital, Brasília, DF, Brazil.
BACKGROUND Uveal melanoma is the most common primary intraocular malignancy in adults, often diagnosed late in resource-limited settings. The diagnosis is made through a combination of clinical ophthalmologic examination, B-mode ultrasound, and histopathological study. This report details a case of a 67-year-old woman with progressive vision loss and ocular pain due to an inferomedial uveal melanoma to highlight therapeutic limitations from delayed diagnosis.
View Article and Find Full Text PDFStem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
August 2025
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
Background: Mogamulizumab is more effective in treating the blood component of mycosis fungoides (MF) and Sezary syndrome (SS), though some patients also experience significant skin improvement. The characteristics distinguishing those with a favorable skin response remain unclear.
Objectives: This study aimed to characterize MF/SS patients achieving skin response on mogamulizumab.
J Invest Dermatol
September 2025
Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha 410008, China; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Furong Laboratory, Changsha, China; Hunan Key Laboratory of Skin Cancer and
Psoriasis is a chronic, immune-mediated inflammatory skin disorder affecting approximately 100 million people worldwide. This study aimed to understand the global impact of psoriasis on health and economics over the past three decades. we analyzed trends in psoriasis cases, its effects on people's quality of life, and the associated costs.
View Article and Find Full Text PDFJ Am Acad Dermatol
September 2025
Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, People's Republic of China; Key Laboratory of skin cancer of Fujian higher education institutions, Fuzhou, Fujian 350000, People's Republic of China; Fujian Provincial Clinical Research Cent
Background: Psoriatic arthritis (PsA) is a condition that can lead to permanent joint deformities. It is crucial to find ways to prevent psoriasis (PsO) from progressing to PsA.
Objectives: To observe the short-term efficacy of biologics on synovitis and enthesitis in subclinical psoriatic arthritis (Sub-PsA) using musculoskeletal ultrasound (MSUS).